DE602004016636D1 - Eine die antitumorwirkung verstärkende verbindung und antitumormittel - Google Patents
Eine die antitumorwirkung verstärkende verbindung und antitumormittelInfo
- Publication number
- DE602004016636D1 DE602004016636D1 DE602004016636T DE602004016636T DE602004016636D1 DE 602004016636 D1 DE602004016636 D1 DE 602004016636D1 DE 602004016636 T DE602004016636 T DE 602004016636T DE 602004016636 T DE602004016636 T DE 602004016636T DE 602004016636 D1 DE602004016636 D1 DE 602004016636D1
- Authority
- DE
- Germany
- Prior art keywords
- antitumor
- antitumor effect
- administering
- enhancing
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003070097 | 2003-03-14 | ||
| PCT/JP2004/003189 WO2004081012A1 (ja) | 2003-03-14 | 2004-03-11 | 抗腫瘍効果増強剤及び抗腫瘍剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004016636D1 true DE602004016636D1 (de) | 2008-10-30 |
Family
ID=32984641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004016636T Expired - Lifetime DE602004016636D1 (de) | 2003-03-14 | 2004-03-11 | Eine die antitumorwirkung verstärkende verbindung und antitumormittel |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9611227B2 (https=) |
| EP (1) | EP1604991B1 (https=) |
| JP (1) | JP4610481B2 (https=) |
| KR (1) | KR100812693B1 (https=) |
| CN (2) | CN101357134A (https=) |
| AT (1) | ATE408408T1 (https=) |
| AU (1) | AU2004220205B2 (https=) |
| BR (1) | BRPI0408372A (https=) |
| CA (1) | CA2518195C (https=) |
| CY (1) | CY1108395T1 (https=) |
| DE (1) | DE602004016636D1 (https=) |
| DK (1) | DK1604991T3 (https=) |
| ES (1) | ES2312978T3 (https=) |
| MX (1) | MXPA05009781A (https=) |
| NZ (1) | NZ542150A (https=) |
| PL (1) | PL1604991T3 (https=) |
| PT (1) | PT1604991E (https=) |
| RU (1) | RU2334517C2 (https=) |
| SI (1) | SI1604991T1 (https=) |
| TW (1) | TW200503720A (https=) |
| WO (1) | WO2004081012A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101135789B1 (ko) * | 2005-04-01 | 2012-04-16 | 다이호야쿠힌고교 가부시키가이샤 | 피리딘 유도체를 유효성분으로 하는 방사선 치료 증강제 |
| DE602006016576D1 (de) * | 2005-04-01 | 2010-10-14 | Taiho Pharmaceutical Co Ltd | Strahlentherapieverstärker |
| WO2007043531A1 (ja) * | 2005-10-07 | 2007-04-19 | Celestar Lexico-Sciences, Inc. | 抗腫瘍剤及び放射線併用療法感受性診断用遺伝子マーカー並びにその利用 |
| AU2008356312B2 (en) * | 2008-05-12 | 2015-04-09 | Shizuoka Prefecture | Antitumor agent, kit, and method for treating cancer |
| JP5553522B2 (ja) * | 2009-03-31 | 2014-07-16 | 大鵬薬品工業株式会社 | 経口投与用医薬組成物 |
| US8992947B2 (en) | 2009-04-22 | 2015-03-31 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of chemotherapy on renal cell cancer |
| CN102309491B (zh) * | 2010-07-02 | 2015-06-10 | 天津金耀集团有限公司 | 一种替加氟、吉美斯特复方注射液 |
| WO2012161240A1 (ja) * | 2011-05-25 | 2012-11-29 | 大鵬薬品工業株式会社 | テガフール、ギメラシル、オテラシルカリウム含有有核錠 |
| HUE053617T2 (hu) * | 2013-09-30 | 2021-07-28 | Taiho Pharmaceutical Co Ltd | Kombinációs rákterápia azabiciklo vegyületet felhasználva |
| CN106692173A (zh) * | 2015-11-18 | 2017-05-24 | 北京诺普德医药科技有限公司 | 一种抗肿瘤复方组合物及其应用 |
| CN106581001B (zh) * | 2016-11-03 | 2018-12-21 | 江苏恒瑞医药股份有限公司 | 一种替吉奥组合物的制备方法 |
| KR102258514B1 (ko) | 2019-09-23 | 2021-05-31 | 연세대학교 산학협력단 | 신규한 다층형 좌약 제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL194430C (nl) | 1989-01-05 | 2002-04-04 | Otsuka Pharma Co Ltd | Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking. |
| DE10299023I2 (de) * | 1990-09-07 | 2010-05-06 | Tahio Pharmaceutical Co Ltd | Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff |
| WO1992021345A1 (en) | 1991-05-27 | 1992-12-10 | Taiho Pharmaceutical Co., Ltd. | Composition, method and kit for potentiating antitumor activity and for curing tumor |
| CH683262A5 (it) * | 1992-01-22 | 1994-02-15 | Applied Pharma Res | Procedimento per la separazione dei diastereomeri del sale di calcio dell'acido (6(R,S)-N-formiltetraidrofolico). |
| AU2001240001A1 (en) * | 2000-03-08 | 2001-09-17 | Bristol-Myers Squibb Company | Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same |
| EE200300429A (et) | 2001-03-06 | 2003-12-15 | Bristol-Myers Squibb Company | Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks |
| JPWO2003004640A1 (ja) * | 2001-07-05 | 2004-10-28 | 大鵬薬品工業株式会社 | 抗癌剤感受性測定用ｄｎａアレイ |
-
2004
- 2004-03-11 JP JP2005503567A patent/JP4610481B2/ja not_active Expired - Lifetime
- 2004-03-11 AT AT04719589T patent/ATE408408T1/de active
- 2004-03-11 BR BRPI0408372-5A patent/BRPI0408372A/pt not_active Application Discontinuation
- 2004-03-11 PL PL04719589T patent/PL1604991T3/pl unknown
- 2004-03-11 WO PCT/JP2004/003189 patent/WO2004081012A1/ja not_active Ceased
- 2004-03-11 KR KR1020057017150A patent/KR100812693B1/ko not_active Expired - Lifetime
- 2004-03-11 EP EP04719589A patent/EP1604991B1/en not_active Expired - Lifetime
- 2004-03-11 SI SI200430955T patent/SI1604991T1/sl unknown
- 2004-03-11 PT PT04719589T patent/PT1604991E/pt unknown
- 2004-03-11 AU AU2004220205A patent/AU2004220205B2/en not_active Ceased
- 2004-03-11 MX MXPA05009781A patent/MXPA05009781A/es active IP Right Grant
- 2004-03-11 RU RU2005131839/15A patent/RU2334517C2/ru active
- 2004-03-11 ES ES04719589T patent/ES2312978T3/es not_active Expired - Lifetime
- 2004-03-11 NZ NZ542150A patent/NZ542150A/xx not_active IP Right Cessation
- 2004-03-11 CN CNA2008101445581A patent/CN101357134A/zh active Pending
- 2004-03-11 CN CNA2004800069779A patent/CN1761665A/zh active Pending
- 2004-03-11 DE DE602004016636T patent/DE602004016636D1/de not_active Expired - Lifetime
- 2004-03-11 CA CA002518195A patent/CA2518195C/en not_active Expired - Fee Related
- 2004-03-11 US US10/548,655 patent/US9611227B2/en not_active Expired - Fee Related
- 2004-03-11 DK DK04719589T patent/DK1604991T3/da active
- 2004-03-12 TW TW093106702A patent/TW200503720A/zh not_active IP Right Cessation
-
2008
- 2008-10-06 CY CY20081101101T patent/CY1108395T1/el unknown
-
2017
- 2017-02-17 US US15/435,493 patent/US9814724B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CY1108395T1 (el) | 2014-02-12 |
| RU2005131839A (ru) | 2006-02-10 |
| CA2518195C (en) | 2009-07-07 |
| SI1604991T1 (sl) | 2009-02-28 |
| US9814724B2 (en) | 2017-11-14 |
| ES2312978T3 (es) | 2009-03-01 |
| ATE408408T1 (de) | 2008-10-15 |
| MXPA05009781A (es) | 2005-10-26 |
| AU2004220205A1 (en) | 2004-09-23 |
| CN1761665A (zh) | 2006-04-19 |
| CN101357134A (zh) | 2009-02-04 |
| US20060116345A1 (en) | 2006-06-01 |
| PT1604991E (pt) | 2008-10-27 |
| WO2004081012A1 (ja) | 2004-09-23 |
| KR20050106119A (ko) | 2005-11-08 |
| RU2334517C2 (ru) | 2008-09-27 |
| EP1604991A1 (en) | 2005-12-14 |
| CA2518195A1 (en) | 2004-09-23 |
| AU2004220205B2 (en) | 2010-06-17 |
| US20170157131A1 (en) | 2017-06-08 |
| EP1604991A4 (en) | 2006-05-03 |
| DK1604991T3 (da) | 2009-01-05 |
| EP1604991B1 (en) | 2008-09-17 |
| KR100812693B1 (ko) | 2008-03-13 |
| BRPI0408372A (pt) | 2006-03-21 |
| JPWO2004081012A1 (ja) | 2006-06-08 |
| JP4610481B2 (ja) | 2011-01-12 |
| PL1604991T3 (pl) | 2009-02-27 |
| US9611227B2 (en) | 2017-04-04 |
| NZ542150A (en) | 2009-09-25 |
| TWI295173B (https=) | 2008-04-01 |
| TW200503720A (en) | 2005-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108395T1 (el) | Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων | |
| TW200637828A (en) | Novel cis-imidazolines | |
| WO2007075554A3 (en) | Combination of igfr inhibitor and anti-cancer agent | |
| TW200728276A (en) | Oxindole derivatives | |
| ATE428411T1 (de) | Hdl-verstärkende kombinationstherapie-komplexe | |
| ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| TN2012000062A1 (en) | Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer | |
| TW200621783A (en) | 1,4 substituted pyrazolopyrimidines as kinase inhibitors | |
| WO2006072589A3 (en) | Disubstituted ureas as kinase inhibitors | |
| IS6925A (is) | Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns | |
| ATE396986T1 (de) | Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken | |
| TW200738698A (en) | Organic compounds | |
| WO2005065266A3 (en) | Di-substituted pyrrolotriazine compounds | |
| IL162384A0 (en) | Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases | |
| PH12022550350A1 (en) | Antimalarial agents | |
| WO2005123068A3 (en) | Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor | |
| BRPI0408238A (pt) | anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer | |
| MY140563A (en) | Antitumor effect potentiator, antitumor preparation | |
| TNSN08287A1 (en) | 3,5-substituted piperidine compounds as renin inhibitors | |
| WO2006135796A3 (en) | Crystalline forms of a pyrrolotriazine compound | |
| SI1553938T1 (sl) | Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma | |
| DK1572715T3 (da) | Steroidforbindelser med antitumor-aktivitet | |
| HK1060518A (en) | Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin | |
| WO2010128346A3 (en) | Rosuvastatin manganse, copper, iron and zinc salts with high photochemical stability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |